Curevac NV and The University of Texas MD Anderson Cancer Center have entered into a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

Spikimm SAS has signed an exclusive collaboration and license option agreement with SATT Conectus Alsace SAS for monoclonal antibodies targeting the BK virus. Reactivation of the BK virus (BKV) in patients receiving kidney transplant, bone marrow or stem cell grafts has potential serious consequences.

Vernalis (R&D) Ltd., a subsidiary of Hitgen Inc., and C4x Discovery Holdings plc have entered into a collaboration to identify modulators of an undisclosed, hard-to-drug, high-value target involved in inflammatory disease.

Mina Therapeutics Ltd. has announced a research collaboration and licensing agreement option with Nippon Shinyaku Co. Ltd. for the discovery and potential development and commercialization of small activating RNA (RNAa) therapeutic candidates targeting rare neurodegenerative diseases for which there are currently no treatment options.

Caris Discovery, the therapeutic research arm of Caris Life Sciences Inc., has established a multiyear strategic partnership with Merck KGaA to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.

Odyssey Therapeutics Inc. has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small-molecule medicines against select therapeutic targets.

Turbine Ltd. and Harmonic Discovery Inc. have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase target (NEK1) identified for cancer dependency.

Ubiquigent Ltd. has signed an agreement with Debiopharm International SA to support the development of Debiopharm’s preclinical ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitor program, Debio-0432.